CD23 and chronic lymphocytic leukemia.
Marika Sarfati
Abstract
Marika Sarfati
Abstract
Chronic lymphocytic leukemia (CLL) is classically defined by the proliferation and accumulation of monoclonal CD5 positive B cells "arrested" at an intermediate stage of differentiation. The CD23 antigen (the low affinity receptor for IgE (Fc epsilon RII) is a 45 kD membrane glycoprotein primarily expressed on surface IgM and IgD positive B cells. The aim of this paper is to establish the link between CD23 and CLL disease and to propose that the CD23 molecule is not simply a marker of CLL disease but may also be involved in the proliferation of the leukemic B cells.
OpenAlex reports 25 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Chronic lymphocytic leukemia (CLL) is classically defined by the proliferation and accumulation of monoclonal CD5 positive B cells "arrested" at an intermediate stage of differentiation. The CD23 antigen (the low affinity receptor for IgE (Fc epsilon RII) is a 45 kD membrane glycoprotein primarily expressed on surface IgM and IgD positive B cells. The aim of this paper is to establish the link between CD23 and CLL disease and to propose that the CD23 molecule is not simply a marker of CLL disease but may also be involved in the proliferation of the leukemic B cells.
Key concepts: CD23, CD5, Chronic lymphocytic leukemia, Immunoglobulin D, Immunoglobulin E, CD20, Antigen, Immunology